SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 36.46 |
| Enterprise Value ($M) | 4.16 |
| Book Value ($M) | 72.72 |
| Book Value / Share | 1.18 |
| Price / Book | 0.50 |
| NCAV ($M) | 48.18 |
| NCAV / Share | 0.78 |
| Price / NCAV | 0.76 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.70 |
| Return on Assets (ROA) | -0.41 |
| Return on Equity (ROE) | -0.54 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 5.15 |
| Current Ratio | 5.15 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 87.22 |
| Assets | 111.75 |
| Liabilities | 39.04 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | Vestal Point Capital, LP | 9.90 | ||
| 13G/A | Lynx1 Capital Management LP | 13.60 | 73.90 | |
| 13D/A | Versant Venture Capital VI, L.P. | 0.00 | -100.00 | |
| 13D/A | Orbimed Advisors Llc | 13.00 | 0.00 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| Y UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| Y UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| Y UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 65,912 | 567,976 | 11.60 | |
| 27,540 | 235,785 | 11.68 | |
| 52,569 | 262,280 | 20.04 | |
| 11,496 | 127,094 | 9.05 | |
| 14,086 | 90,851 | 15.50 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| OPTN – OptiNose, Inc. | ORIC – ORIC Pharmaceuticals, Inc. |
| OVID – Ovid Therapeutics Inc. | PBYI – Puma Biotechnology, Inc. |
| PCRX – Pacira BioSciences, Inc. |
Financial data and stock pages provided by
Fintel.io